Alvotech, a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, amended its existing credit agreement with funds managed by GoldenTree Asset Management and other existing lenders of Alvotech to provide a term loan facility of up to $75 million in additional capital.
The financing further strengthens Alvotech’s financial position following the $165 million equity capital raise announced on June 18, 2026, and supports the continued execution of the company’s growth strategy, including advancing its biosimilar pipeline, supporting product launches and expanding global commercial operations. Including the equity financing and the undrawn term loan facility, the company has secured access to $240 million in new capital.
“This financing provides additional flexibility as we continue to execute on our strategic priorities and support the next phase of growth for Alvotech,” Robert Wessman, founder and chairman of Alvotech, said. “The strong support we received from both existing shareholders and more than 40 new specialist healthcare investors in our recent equity offering, together with this additional financing, reflects growing confidence in Alvotech, our strategy and the opportunities ahead.”
Wessman continued, “Over the past several months we have achieved important milestones across our business, including the resubmission of key Biologics License Applications to the FDA, continued advancement of our pipeline including FDA acceptance of our BLA for a biosimilar to Entyvio, and the expansion of our global commercial footprint. These achievements reinforce our belief that we are building one of the world’s leading biosimilars companies.”
Wessman concluded, “With approximately 30 biosimilar products in development and a growing portfolio of commercial opportunities, we see a significant opportunity to increase patient access to affordable biologic medicines around the world. Capital is the fuel that enables us to execute on that vision, and this financing further strengthens our ability to invest in growth and create long-term value for patients, partners and shareholders.”
The financing builds on Alvotech’s existing relationship with GoldenTree, which has been a long-term financing partner to the company. It expands the company’s existing credit agreement by providing an additional $75 million term loan facility alongside the $100 million term loan facility announced in December 2025. It bears an interest rate of 12.50%, payable monthly in cash, and has a maturity date of Dec. 31, 2027.
